Human post-implantation embryo models show promise in unraveling early development

Researchers evaluate post-implantation development in humans using embryo-like models based on genetically unmodified human naïve embryonic stem cells.

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress – Biotech Investments

Issuer: CureVac / Key word(s): Conference/Study results 13.09.2024 / 13:57 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac’s CVGBM Cancer

September 14, 2024

Viralgen and Axovia to develop gene therapy for retinal dystrophy

Viralgen will manufacture the therapy at its facility. Credit: Viralgen/PRNewswire. Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and

January 23, 2025

Janssen submits sBLA to FDA for NSCLC combination therapy

Janssen is seeking FDA approval for the combination therapy of RYBREVANT plus chemotherapy for NSCLC. Credit: user:ekem / commons.wikimedia.org. The Janssen Pharmaceutical Companies of Johnson &

August 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.